ImmuCell names Olivier te Boekhorst as CEO, adds board members

ImmuCell Corporation (NASDAQ: ICCC) announced that Olivier te Boekhorst began serving as president and CEO on November 1, 2025, replacing Michael F. Brigham. The Portland, Maine-based animal health company also appointed te Boekhorst and Timothy C. Fiori to its board of directors on October 29, 2025.

Fiori, who joined ImmuCell as CFO in April 2025, will also serve as treasurer and secretary. The company stated Fiori brings 24 years of finance and commercial operating experience in the livestock industry. Brigham will remain on the board and serve as special advisor to the CEO until January 2026.

ImmuCell develops, manufactures and markets products for dairy and beef cattle health. The company produces First Defense, a product for newborn calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows.

The company plans to host a conference call on November 14, 2025, at 9:00 AM ET to discuss third quarter financial results for the period ended September 30, 2025. The call will be accessible by dialing (844) 855-9502 for toll-free access or (412) 317-5499 for international callers.

A replay will be available until November 21, 2025, at (877) 344-7529 toll-free or (412) 317-0088 international, using access code 7664668. The company expects to release an updated corporate presentation slide deck after market close on November 13, 2025.

You May Also Be Interested In

• Profound Medical names Richard Fabian as president
• Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
• Helix and Hornbeck complete all-stock merger, form new NYSE: HOS